Michelle Poon

Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial

Catherine Thiéblemont, Tycel Phillips, Hervé Ghesquières et al. · Journal of Clinical Oncology · 2022 · 523 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial

Catherine Thiéblemont, Yasmin Karimi, Hervé Ghesquières et al. · Leukemia · 2024 · 119 citations · Full text

Medicine, Oncology, Hematologic Oncology +7

Multi-center analysis of the effect of T-cell acute lymphoblastic leukemia subtype and minimal residual disease on allogeneic stem cell transplantation outcomes

Jonathan E. Brammer, Rima M. Saliba, Jeffrey L. Jorgensen et al. · Bone Marrow Transplantation · 2016 · 55 citations · Full text

Medicine, Hematology, Oncology +17

Final Analysis of the Phase 2 ELM-2 Study: Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Sabarish Ayyappan, Won Seog Kim, Tae Min Kim et al. · Blood · 2023 · 48 citations

Medicine, Oncology, Pharmacotherapy +12

Comparison of outcomes at two institutions of patients with ALL receiving ex vivo T-cell-depleted or unmodified allografts

Gabriela Hobbs, Amir Hamdi, Patrick Hilden et al. · Bone Marrow Transplantation · 2015 · 38 citations · Full text

Life Sciences, Immunology, Surgery +12